Business Context and Reporting Period
This Form 8-K Current Report was filed by MRI Interventions, Inc. (not Clearpoint Neuro, Inc.) on May 9, 2019. The filing discloses the entry into a material definitive agreement for a private placement financing transaction and the appointment of a new director.
Key Financial Metrics
The filing does not provide specific revenue, profit, cash flow, margin, or debt figures. The primary financial metric disclosed is the proposed financing transaction:
- Securities Offered: Up to 2,682,000 shares of common stock.
- Price Per Share: $3.10.
- Committed Purchase: Approximately 1,743,068 shares by initial investors.
- Reserved Shares: Remaining shares reserved for participation rights by 2017 investors (exercise not guaranteed).
- Expected Closing: On or about May 17, 2019.
Material Changes
The filing reports the following material changes effective upon the closing of the financing:
- Capital Structure: Anticipated issuance of up to 2,682,000 new shares of common stock.
- Board Composition: The Board of Directors increased in size from six to seven members.
- Corporate Governance: PTC Therapeutics, Inc. (PTC) was granted the right to designate a director nominee to the Board until PTC no longer beneficially owns at least 500,000 shares.
Guidance, Outlook, and Risks
Management Commentary and Rights:
- PTC Rights: PTC received registration rights and the right to participate in future financings for up to 24 months or until its ownership drops below 500,000 shares, allowing it to maintain its pro-rata ownership or up to 10.5% of the financing, whichever is greater.
- New Director: Marcio Souza, currently COO of PTC, was appointed as a new director. He will serve without compensation but is entitled to standard indemnification and insurance benefits.
Risks and Contingencies:
- Closing Conditions: The sale of securities is subject to customary closing conditions; there is no assurance the transaction will close on the anticipated date or at all.
- Participation Rights: There is no assurance that the 2017 investors will exercise their participation rights to purchase the reserved shares.
- Forward-Looking Statements: Actual results may differ materially due to market conditions and satisfaction of closing conditions.
Investor Verification Checklist
- Verify the actual closing date and total proceeds raised once the transaction is completed.
- Confirm whether the 2017 investors exercised their participation rights to purchase the reserved shares.
- Review the full text of the Securities Purchase Agreement (Exhibit 10.1) for specific covenants and restrictions.
- Monitor the Company's liquidity position post-closing to assess runway for operations.
- Check subsequent filings for the official election of Marcio Souza at the 2019 annual stockholders meeting.